Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2002 4
2003 3
2004 9
2005 7
2006 2
2007 6
2008 10
2009 9
2010 7
2011 12
2012 15
2013 11
2014 9
2015 22
2016 17
2017 12
2018 8
2019 15
2020 12
2021 16
2022 14
2023 13
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

218 results

Results by year

Filters applied: . Clear all
Page 1
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Dorman SE, et al. N Engl J Med. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400. N Engl J Med. 2021. PMID: 33951360 Free PMC article. Clinical Trial.
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE; BRIEF TB/A5279 Study Team. Swindells S, et al. Among authors: nuermberger e. N Engl J Med. 2019 Mar 14;380(11):1001-1011. doi: 10.1056/NEJMoa1806808. N Engl J Med. 2019. PMID: 30865794 Free PMC article. Clinical Trial.
Confronting multidrug-resistant tuberculosis.
Chaisson RE, Nuermberger EL. Chaisson RE, et al. Among authors: nuermberger el. N Engl J Med. 2012 Jun 7;366(23):2223-4. doi: 10.1056/NEJMe1204478. N Engl J Med. 2012. PMID: 22670908 No abstract available.
The Many Hosts of Mycobacteria 9 (MHM9): A conference report.
Klever AM, Alexander KA, Almeida D, Anderson MZ, Ball RL, Beamer G, Boggiatto P, Buikstra JE, Chandler B, Claeys TA, Concha AE, Converse PJ, Derbyshire KM, Dobos KM, Dupnik KM, Endsley JJ, Endsley MA, Fennelly K, Franco-Paredes C, Hagge DA, Hall-Stoodley L, Hayes D Jr, Hirschfeld K, Hofman CA, Honda JR, Hull NM, Kramnik I, Lacourciere K, Lahiri R, Lamont EA, Larsen MH, Lemaire T, Lesellier S, Lee NR, Lowry CA, Mahfooz NS, McMichael TM, Merling MR, Miller MA, Nagajyothi JF, Nelson E, Nuermberger EL, Pena MT, Perea C, Podell BK, Pyle CJ, Quinn FD, Rajaram MVS, Mejia OR, Rothoff M, Sago SA, Salvador LCM, Simonson AW, Spencer JS, Sreevatsan S, Subbian S, Sunstrum J, Tobin DM, Vijayan KKV, Wright CTO, Robinson RT. Klever AM, et al. Among authors: nuermberger el. Tuberculosis (Edinb). 2023 Sep;142:102377. doi: 10.1016/j.tube.2023.102377. Epub 2023 Jul 23. Tuberculosis (Edinb). 2023. PMID: 37531864 Review.
New drugs and regimens for tuberculosis.
Chang KC, Nuermberger E, Sotgiu G, Leung CC. Chang KC, et al. Among authors: nuermberger e. Respirology. 2018 Nov;23(11):978-990. doi: 10.1111/resp.13345. Epub 2018 Jun 19. Respirology. 2018. PMID: 29917287 Review.
Discovery of natural-product-derived sequanamycins as potent oral anti-tuberculosis agents.
Zhang J, Lair C, Roubert C, Amaning K, Barrio MB, Benedetti Y, Cui Z, Xing Z, Li X, Franzblau SG, Baurin N, Bordon-Pallier F, Cantalloube C, Sans S, Silve S, Blanc I, Fraisse L, Rak A, Jenner LB, Yusupova G, Yusupov M, Zhang J, Kaneko T, Yang TJ, Fotouhi N, Nuermberger E, Tyagi S, Betoudji F, Upton A, Sacchettini JC, Lagrange S. Zhang J, et al. Among authors: nuermberger e. Cell. 2023 Mar 2;186(5):1013-1025.e24. doi: 10.1016/j.cell.2023.01.043. Epub 2023 Feb 23. Cell. 2023. PMID: 36827973 Free PMC article.
Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
Tasneen R, Garcia A, Converse PJ, Zimmerman MD, Dartois V, Kurbatova E, Vernon AA, Carr W, Stout JE, Dooley KE, Nuermberger EL. Tasneen R, et al. Among authors: nuermberger el. Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0239821. doi: 10.1128/aac.02398-21. Epub 2022 Mar 22. Antimicrob Agents Chemother. 2022. PMID: 35315690 Free PMC article.
Restocking the tuberculosis drug arsenal.
Nuermberger EL, Chaisson RE. Nuermberger EL, et al. Nat Med. 2024 Mar;30(3):642-643. doi: 10.1038/s41591-024-02840-y. Nat Med. 2024. PMID: 38459183 No abstract available.
Minding the gaps in tuberculosis research.
Ekins S, Nuermberger EL, Freundlich JS. Ekins S, et al. Among authors: nuermberger el. Drug Discov Today. 2014 Sep;19(9):1279-82. doi: 10.1016/j.drudis.2014.06.022. Epub 2014 Jun 30. Drug Discov Today. 2014. PMID: 24993157 No abstract available.
218 results